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Background: Efforts to uncover the risk genotypes associated with the familial nature of autism spectrum disorder
(ASD) have had limited success. The study of extended pedigrees, incorporating additional ASD-related phenotypes
into linkage analysis, offers an alternative approach to the search for inherited ASD susceptibility variants that
complements traditional methods used to study the genetics of ASD.
Methods: We examined evidence for linkage in 19 extended pedigrees ascertained through ASD cases spread
across at least two (and in most cases three) nuclear families. Both compound phenotypes (i.e., ASD and, in
non-ASD individuals, the broad autism phenotype) and more narrowly defined components of these phenotypes,
e.g., social and repetitive behavior, pragmatic language, and anxiety, were examined. The overarching goal was to
maximize the aggregate information available on the maximum number of individuals and to disaggregate
syndromic phenotypes in order to examine the genetic underpinnings of more narrowly defined aspects of ASD
behavior.
Results: Results reveal substantial between-family locus heterogeneity and support the importance of previously
reported ASD loci in inherited, familial, forms of ASD. Additional loci, not seen in the ASD analyses, show evidence
for linkage to the broad autism phenotype (BAP). BAP peaks are well supported by multiple subphenotypes
(including anxiety, pragmatic language, and social behavior) showing linkage to regions overlapping with the
compound BAP phenotype. Whereas ‘repetitive behavior’, showing the strongest evidence for linkage (Posterior
Probability of Linkage = 62% at 6p25.2-24.3, and 69% at 19p13.3), appears to be linked to novel regions not
detected with other compound or narrow phenotypes examined in this study.
Conclusions: These results provide support for the presence of key features underlying the complexity of the
genetic architecture of ASD: substantial between-family locus heterogeneity, that the BAP appears to correspond to
sets of subclinical features segregating with ASD within pedigrees, and that different features of the ASD
phenotype segregate independently of one another. These findings support the additional study of larger, even
more individually informative pedigrees, together with measurement of multiple, behavioral- and biomarker-based
phenotypes, in both affected and non-affected individuals, to elucidate the complex genetics of familial ASD.
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Autism spectrum disorder (ASD), a neurodevelopmental
condition associated with lifelong disability, has now be-
come an urgent public health challenge. Research into
the genetics of ASD is motivated by the very real possi-
bility that genetic testing can play a role in improving
the diagnostic process and in providing targets for the
development of new drugs [1]. However, much remains
to be learned about the genetics of ASD before these
goals are realized.
Early family studies based on retrospective data found
a 2–9% recurrence of ASD among siblings of affected
probands [2]. Recent work using prospective data and
more up to date criteria [3] observed closer to 1 in 4 sib-
lings affected – roughly 25 times higher than in the gen-
eral population. Not only is the disorder familial, but
variation in phenotypes such as IQ and language appear
to be correlated among affected siblings as well [4-6].
Twin studies demonstrate that concordance for a pheno-
type that includes both autism and milder cognitive and
social-communication deficits and rigidity (termed the
broader autism phenotype or BAP), was >80% among
monozygotic twins, compared with ~10% in dizygotic
twin pairs [7], although the dizygotic rate is substantially
higher in the most recent twin study [8]. This BAP also
appears more common in relatives (particularly parents)
of ASD probands than controls (20% vs. <10%) and
more commonly in male than female relatives of ASD
probands [9-11]. A recent prospective study of high-risk
infant siblings indicates that this same extended pheno-
type (BAP traits, cognitive delays, and anxious behav-
iors) can be seen in upwards of 20% of infant siblings
(who do not go on to develop ASD) compared to 3% in
low-risk controls [12]. These combined findings indicate
that ASD is a familial disorder (with roughly 40% of
siblings showing either ASD or an extended BAP) with a
strong genetic component.
However, studies attempting to uncover the risk geno-
type associated with the familial nature of the disorder
have been largely unsuccessful. A review of linkage stud-
ies using mostly affected sibling pairs has indicated
many ‘significant’ linkage peaks with some replication
among linkage signals [13]. Fine mapping under the
peaks has not been successful in uncovering ASD genes,
likely due to, among other reasons, a degree of allelic
heterogeneity that, in retrospect, was greater than antici-
pated and perhaps by an over-reliance on the compound
phenotype of ASD as opposed to a more modular ap-
proach. Four large independent genome-wide association
studies have been reported, but so far the data indicate
that few, if any, common variants have a substantial im-
pact on risk [14-17]. A recent cross-disorder genome-wide
association study reports more promising results, but spe-
cificity of those common variants to ASD is unclear [18].In startling contrast, there is substantial evidence that
a multitude of rare de novo copy number variants
(CNVs) contribute, at least in part, to the etiology of
sporadic (i.e., non-familial) ASD [19,20]. To quantify the
role of CNVs, a series of large studies (for a review see
[21]), have used microarrays to interrogate ASD cohorts.
Although estimates vary among studies, between 2% to
10% of probands appear to have de novo structural vari-
ants [21,22]. Every risk locus or gene so far occurs with
less than 1% frequency in ASD cases.
The field has been more likely to assign a causal role
to de novo CNVs than to inherited ones in spite of the
fact that ASD is a familial disorder and that rare
inherited CNVs have also been consistently reported in
ASD. Several pedigrees showing inherited CNVs or point
mutations in a number of key CNS genes or regions
(SHANK1, CDH8, NRXN3, PTCHD1, 16p11.2) have
also been published [23-27]. In many of these, the trans-
mitting parent had the BAP or a related phenotype; for
example, in a pedigree transmitting a SHANK1 deletion,
we determined that the transmitting parents (both
mothers) had suffered from anxiety disorders [26] (such
disorders were not present in non-transmitting relatives
who we were able to assess). In other pedigrees, med-
ical/congenital or cognitive abnormalities in relatives
also appear to be segregating with a rare variant. How-
ever, these represent single case reports and it is there-
fore hard to argue that these phenotypes are variable
expressions of the ASD genotype at the population level
as opposed to the individual case level.
The study of extended pedigrees (defined here as in-
cluding relatives outside of the nuclear family identified
by an ASD proband) offers an opportunity to study the
inherited nature of ASD more thoroughly. Such pedi-
grees may have enough information to be able to follow
the segregation of a genetic variant through a single
family to see if it is associated with phenotype status.
Several groups have employed the extended pedigree
strategy, ranging from a search for shared CNVs across
cousin pairs to studying a single, extensive Finnish pedi-
gree from 20 nuclear families [28-32]. One study incor-
porated measurement of the social responsiveness scale
subphenotype into the analysis of extended pedigrees and
concluded that this was a robust and useful approach for
exploring genetic linkage in studies of ASD [30]. If an im-
portant goal is to understand the familial nature of ASD, a
greater focus on inherited variants is warranted employing
a broad range of phenotypes including those segregating in
parents and siblings without ASD. However, there are no
systematic linkage studies on whether non-ASD individ-
uals with a potentially pathogenic variant have any pheno-
type of interest such as the BAP and related phenotypes.
Incorporating additional phenotypes into linkage ana-
lysis may be a robust way to uncover inherited ASD
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increases the risk of ASD and which can also produce a
sub-clinical phenotype in mutation carriers. Misclassify-
ing carriers as ‘unaffected’ artificially reduces penetrance
estimates for linkage analysis, while misclassifying non-
carriers as ‘affected’ introduces apparent phenocopies;
either of these errors will tend to depress linkage signals.
Thus, in a set of pedigrees segregating this mutation, the
more accurately the sub-clinical phenotype is measured,
the stronger the linkage evidence should be. In other
words, a clinical definition that correctly captures the
segregation pattern of the mutation will, all other
things being equal, result in stronger linkage evidence.
Similarly, a quantitative trait (QT) that correctly
segregates with the mutation will produce stronger link-
age evidence, in general, than one that does not.
Here, we utilize clinical data on several ASD-related
phenotypes in conjunction with linkage analysis of
extended pedigrees to explore genotype-phenotype
relationships in ASD.
Methods
Participants
We recruited extended pedigrees with at least three
ASD cases spread across at least two nuclear families (in
all but one case, the three cases were spread across three
nuclear families). All families were either known to the
authors through previous studies or identified through
advertising. In all, 19 families were available for this
study, 6 recruited in Canada (CA) and 13 in the US. The
CA pedigrees had an average of 24 genotyped individ-
uals and 25 phenotyped individuals, while the US pedi-
grees had an average of 16 genotyped individuals and 18
phenotyped individuals. To minimize etiologic hetero-
geneity, families were excluded from the study if there
was evidence of the following co-occurring medical
conditions thought to be etiologically-related to autism
in one of the index probands with autism: tuberous
sclerosis, neurofibromatosis, phenylketonuria, Fragile X
screening, or significant CNS injury. We did not exclude
individuals with a chromosome abnormality in order to
determine whether that abnormality might also be
inherited and play a role in susceptibility. All individuals
were of northern European heritage. All data collection
took place under Institutional Review Board approval
and the research was conducted in accordance with the
World Medical Association Declaration of Helsinki [33].
Written informed consent was obtained from all subjects
after the study had been fully explained.
Clinical methods
Our overarching clinical strategy included clinical as-
sessments performed to i) index eligible extended pedi-
grees, by identifying at least three related individualswith a Diagnostic and Statistical Manual (4th ed) (DSM-IV)
pervasive developmental disorder; and to ii) characterize
all pedigree members on phenotypes of interest. For the
latter goal of characterizing pedigree members, the
strategy employed was to assess for both compound
phenotypes (i.e., ASD or, in non-ASD individuals, the
BAP) and more narrowly defined components of these
phenotypes including social and repetitive behavior,
pragmatic language, and anxiety. The overarching goal
in taking this multi-tiered approach was to maximize
the aggregate information available on the maximum
number of affected individuals (i.e., global ratings of
ASD or the BAP) as well as to disaggregate these global
phenotypes to look at the genetic underpinnings of
individual behavioral aspects of the broad construct of
autistic behavior.
Overlapping sets of instruments were used to diagnose
ASD and the BAP in the CA and US pedigrees, respect-
ively. After initial screening based on the Telephone
Screening Interview, the Autism Family History Inter-
view [34], and review of medical records, diagnosis was
based on expert clinical judgment incorporating infor-
mation from the Autism Diagnostic Interview Revised
[35] and Autism Diagnostic Observation Schedule –
Revised [36], administered by trained and reliable
clinicians. All participants classified as ASD met DSM
IV criteria [37] for either Autistic disorder, Asperger syn-
drome, or pervasive developmental disorder not other-
wise specified according to the criteria in Risi et al. [38].
The US extended pedigrees included 3 to 6 individuals
with ASD (average = 4); while the CA extended pedi-
grees included 3 to 8 (average = 5).
Non-ASD family members were assessed for BAP,
which broadly covers the domains of aloof personality,
rigid personality, and pragmatic language deficits. The
Modified Personality Assessment Schedule Revised
(MPAS-R) [39,40] and Modified Pragmatic Rating Scale
(MPRS) [39,40], which are the preferred methods for
BAP assessment in individuals aged 16 or over, were ad-
ministered only to the US families. The MPAS-R [41] is
a semi-structured interview for rating personality char-
acteristics adapted from the Personality Assessment
Schedule [42], further revised to assess six personality
characteristics: aloof, anxious, hypersensitive, overly-
conscientious, rigid, and untactful [40]. In the MPAS-R,
information is collected via separate self and informant
interviews and the characteristics are rated as either
present, absent or unknown [39] by two independent cli-
nicians, with a third rater serving as a tiebreaker when
needed. For this study, only two MPAS-R characteristics
(aloof and rigid) were utilized in determining the BAP,
although all characteristics were queried and rated to
maintain the integrity of the instrument. Aloof and rigid
have consistently been the most valid and reliable at
Table 1 Cut-off scores for BAP-Q self and informant
ratings, and the average of the two, for males and
females
Male Female
Aloof Self: 4.13 Self: 3.45
Informant: 4.19 Informant: 3.64
Average: 4.03 Average: 3.39
Pragmatic language Self: 3.23 Self: 2.94
Informant: 3.29 Informant: 3.19
Average: 3.09 Average: 2.90
Rigidity Self: 3.91 Self: 3.70
Informant: 4.20 Informant: 4.30
Average: 3.90 Average: 3.85
Total score Self: 3.55 Self: 3.17
Informant: 3.63 Informant: 3.46
Average: 3.47 Average: 3.19
Original ‘best estimate’ cut-off scores reported by Hurley et al. [45] were as
follows: Male: Aloof 3.25, Pragmatic Language: 2.95, Rigid: 3.65; Total Score:
3.35; Female: Aloof 3.00, Pragmatic Language: 2.70, Rigid: 3.25; Total Score:
3.25.
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relatives of typically developing individuals in our previ-
ous studies (e.g., Piven et al. [40]). The MPRS is an ab-
breviated version of the pragmatic rating scale (PRS)
[43], developed to identify seven pragmatic language
skills and four prosodic and grammatical speech errors
with more efficiency and less redundancy than the PRS.
These eleven items were extracted from the PRS using
logistic regression to determine those that most reliably
predict pragmatic speech deficits; they best differentiated
parents of children with autism and parents of typically
developing children in the Iowa Family Study [40], are
highly correlated to the PRS, and were validated during
the Collaborative Linkage Study of Autism [44]. Trained
interviewers rate items 0, 1, or 2 based on a guided con-
versation incorporated in the MPAS-R that ensures that
all rated behaviors have the opportunity to be observed.
The PRS has good inter-rater reliability (κ = 0.77)
[40,43].
When MPAS-R and MPRS consensus ratings were not
available, as for all CA pedigrees and some US individ-
uals, the BAP Questionnaire (BAP-Q) [45] was used for
diagnosis of the BAP and components (aloof and rigid
personality, and pragmatic language deficits). The BAP-
Q was also used as a screening tool and mailed to partic-
ipants to determine whether or not to follow-up with
more comprehensive BAP assessment or to gather ‘diag-
nostic’ information on participants who were otherwise
unavailable for in-person visits. The BAP-Q is a self-
and informant-report questionnaire consisting of 36
items spread across three 12-item subscales derived from
direct assessment interviews (social aloofness and rigid
personality from the MPAS-R and pragmatic language
abnormalities from the MPRS). Items are rated along a
six-point Likert scale (ranging from ‘very rarely’ to ‘very
often’), which forces ratings to fall above or below a
value of neutral on each question. Original internal
consistency analysis of the subscales [45] supported this
three-component model, which is consistent with the
traditional conceptualizations of domains characterizing
autism: social, communication and restricted and repeti-
tive behaviors. The measure was completed by the par-
ticipant about him/herself (the self-version) and by
someone close to the participant about him/her (the in-
formant version) to obtain an average score (between
the self and informant scores); whenever available, the
average scores were utilized. A BAP diagnosis was
assigned if an individual met gender-specific criteria in
any domain [46] (see Table 1 for cut-offs). These diagnos-
tic cut-offs are higher than those originally published in
2007 and have higher specificity than the 2007 cut-offs
now suggested for use in screening. The US pedigrees had
a range of 2 to 10 BAP positive cases (average = 5); the
CA pedigrees had a range of 1 to 6 BAP positive cases(average = 4). Note that when analyzing ASD alone, BAP
positive individuals were coded as unaffected.
The US (but not CA) families were additionally
assessed on seven secondary phenotypes. The second-
ary US phenotypes address various aspects of autism
and include anxiety (ANX), repetitive/ritualistic behav-
ior (RRB), social functioning (SOC), and language
abnormalities, i.e., social communication (PRS), core
language ability (CLF), non-word repetition (NWR),
and rapid naming (RAP). The CL, NWR, and RAP phe-
notypes were considered exploratory as there is less
support for these constructs showing familiality in the
literature, and were added to enrich the overall assess-
ment for communication phenotype information, one
of three major criteria for autism in the DSM IV.
ANX, RRB, and SOC are quantitative variables. ANX
is based on the anxiety (N1) facet t-score of the NEO
Personality Inventory Revised [47], given to non-ASD
family members aged 17 and over (reported to aggregate
in parents of autistic probands [40]). Since ANX was not
measured in ASD cases, a quantitative trait threshold
model was used, designating ASD cases as ‘over thresh-
old’ and non-cases as under (when no ANX score was
available). Observed ANX has a bell-shaped distribution
with an overall mean score of 51 (SD = 9), and the
within-pedigree means ranged from 47 to 63. RRB is the
overall score from the Repetitive Behavior Scale Revised
[48], and has an overall mean of 13 (SD = 16) and is
higher in ASD cases (mean = 26, SD = 16) than non-
cases (mean = 4, SD = 7). Mean pedigree RRB varies
greatly from 6 to 31. SOC is the total t-score from the
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is skewed right with an overall mean of 55 (SD = 18)
and is also greater in ASD cases (mean = 84, SD = 14)
than non-cases (mean = 48, SD = 11). Mean pedigree
SOC is fairly stable with a range of 48 to 67.
The remaining variables are dichotomous. PRS is
based on ASD status and the social score of the MPRS,
used above to diagnose BAP; 61% of those assessed with
MPRS were positive on PRS and 24% of non-ASD cases
were positive on PRS. All ASD positive individuals were
considered as affected for PRS. The pedigrees have
between 6 and 10 PRS cases. CLF affection indicates
a standard core language score from the Clinical
Evaluation of Language Fundamentals 4th Edition below
84 (1 SD below the mean) [50]. Half of ASD cases were
positive on CLF while only 2% of non-cases were posi-
tive. Families had at most three CLF cases. NWR and
RAP are phenotypes derived from performance on the
Comprehensive Test of Phonological Processing [51]:
NWR cases have non-word repetition subtest standard
scores ≤7 (1 SD below the mean), and RAP cases have
rapid naming composite scores <84 (1 SD below the
mean) [52]. For NWR, 41% of ASD cases were positive
compared to 23% of non-cases. Similarly for RAP, 46%
of ASD cases were positive versus 11% of non-cases.
The extended pedigrees have at most 9 or 7 cases of
NWR or RAP, respectively, but there are pedigrees with
none for both phenotypes.
Genotyping and data cleaning
Three hundred and twenty-two individuals (range 7–32,
mean 17/pedigree) were genotyped using a dense micro-
satellite (MS) marker set (avg. intermarker distance
4 cM) obtained from DeCode; 280 individuals (range
6–29, mean 15/pedigree) were also genotyped using the
Illumina OMNI 2.5 M chip. In preparation for linkage
analysis, both MS and SNP data were used to verify
family structure; founders were assessed for relatedness
(no relatedness found), and extended relationships
were confirmed. All genotypes were cleaned for marker
missingness (dropping markers above thresholds of
5% for SNPs, 25% for MSs), sample missingness (>5%
SNP; >25% MS), and excess Mendel errors both by
marker and individual; SNPs with a Hardy-Weinberg p
value <1x10-10 and MSs below 1x10-4 were dropped.
After thinning of the SNP map to remove marker-
marker linkage disequilibrium (R2 >0.20), we based link-
age analyses on a combined map comprising 10,364
SNPs + 1,078 MSs. The genetic map was based on the
Build 36 hg18 (Build 37 hg19 used for X only) Rutgers
Combined Linkage-Physical Map (http://compgen.
rutgers.edu/RutgersMap) [53] (custom release November
2011). The full set of (pre-thinned) SNPs was also used to
call CNVs. No CNVs were observed to segregate withinpedigrees and they are therefore not further discussed in
this paper.
Statistical methods
Linkage analysis was conducted using the software pack-
age KELVIN, which implements the PPL class of models
for measuring the strength of genetic evidence [54,55].
(“PPL” originally stood for “posterior probablity of link-
age.”) In order to take advantage of the very dense
marker coverage and given the size of the pedigrees,
MCMC was used to calculate marker likelihoods as de-
scribed in [56], while KELVIN’s non-stochastic algorithm
was used to calculate trait likelihoods conditional on
marker data [57]. We note that these calculations are
highly computationally intensive, requiring approxi-
mately 36,000 CPU hours (1-month real time) with cal-
culations distributed over a 90-node Linux cluster with
16–128 Gb memory/node.
Three different trait models were employed, depending
on the type of trait being analyzed: dichotomous trait
(DT, used for ASD, BAP, CLF, NWR, PRS and RAP),
quantitative trait (QT, used for RRB, SOC), and QT
threshold (QTT, used for ANX). The DT model is pa-
rameterized in terms of α (the admixture parameter of
Smith [58], representing the proportion of ‘linked’ pedi-
grees), p (the disease allele frequency), and the pene-
trance vector fi, representing the probability that an
individual with genotype i develops disease, for i – 1..3.
The QT model replaces the penetrances with a vector of
three genotypic means and three genotypic variances.
Note that normality is assumed at the genotypic level,
but not at the population level, and there is no inflation
of scores under violations of normality [59]. The QTT
model extends the QT model by allowing for ‘affected’
individuals, who are missing QT values but assumed to
have exceeded some threshold on the QT scale, with the
threshold itself being an additional parameter of the
model. All trait parameters are integrated out of the final
statistic, using essentially uniform prior distributions (or-
dering constraints are imposed on the penetrances or
means), and unbounded parameters are integrated over
a finite range [54,59], implicitly allowing for dominant,
recessive, and additive models. This provides a robust
approximation for mapping complex traits in terms of
the marginal model at each locus, and because the pa-
rameters are integrated out, no specific assumptions re-
garding their values are required.
The PPL has two basic approaches to the accumula-
tion of evidence, which we employ here to consider evi-
dence across pedigrees. Under ‘pooled’ (PPLPOOL), the
trait parameters are integrated across all pedigrees as a
set at each locus. This is appropriate under the expect-
ation that at each locus, the trait model is essentially the
same across pedigrees. Under ‘sequential’ (PPLSEQ), trait
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gree at each locus, and the marginal evidence for or
against linkage itself is accumulated across pedigrees
using Bayesian sequential updating. Sequential updating
is appropriate under the expectation that each pedigree
may implicate different loci and/or the same loci but
under different trait models (as could arise, e.g., in the
presence of important background genetic and/or envir-
onmental modification). When there is relative genetic
homogeneity, pooling will yield larger signals at linked
loci; when there is extensive heterogeneity, however, se-
quential will yield larger signals at linked loci and also
smaller signals at unlinked ones [60].
Since the PPL framework differs from standard
frequentist statistical approaches, a few comments on
its interpretation will be helpful. First, the PPL is on
the probability scale, and its interpretation is therefore
straightforward, e.g., PPL = 40%, means that there is an
estimated 40% probability of a trait gene at the given
location based on the data. The only caveat to this in-
terpretation is that this estimated probability is
influenced by the low prior probability of linkage (π) to
any given locus. Based on empirical data [61] we set
π = 2% (this assumes just one disease gene in the gen-
ome and is thus conservative, possibly highly conser-
vative, under locus heterogeneity). Thus PPL >2%
indicates (some degree) of evidence in favor of a trait
gene at that locus, while PPL <2% represents evidence
against the location. As with any Bayesian method, the
influence of this small prior probability on the final
PPL can be appreciable until the data set becomes
large. Hence, even a small PPL – say, 20% – indicates
that the data are supporting linkage enough to make
the posterior probability 10 times larger than the prior.
Hence, in finite samples, we do not interpret 1-PPL as
the probability of no gene; rather, we interpret the PPL
relative to the prior probability π = 2%.
Additional distinctive features of the statistical frame-
work are related to the fact that the PPL is a measure of
statistical evidence, not a decision-making procedure.
There are, therefore, no ‘significance levels’ associated
with it (i.e., no specific cut-offs beyond which we declare
significance) and it is not interpreted in terms of associ-
ated error probabilities [62,63]. By the same token, no
multiple testing corrections are applied to the PPL, just
as one would not ‘correct’ a measure of the temperature
made in one location for temperature readings taken at
different locations [64].
Results
The results are presented in four sections: i) we con-
sider the comparison between pooled and sequentially
updated results for both ASD and BAP, in order to
gauge the extent of between-family heterogeneity, andthen present primary ii) ASD and iii) BAP results,
followed by iv) results for the secondary phenotypes.i) Pooling vs. sequential updating
Figure 1a shows pooled and sequential results across the
genome for ASD, while Figure 1b shows results for BAP.
Within each sub-figure, results are correlated, as expected.
However, for ASD, there was just 1 PPLPOOL ≥0.20, but 4
under sequential (max PPLSEQ = 0.41, at the same position
as PPLPOOL = 0.20); while for BAP the corresponding num-
bers were 1 (PPLPOOL = 0.41) and 5 (with max PPL = 0.46
at that same position). Across the board, where PPL >10%,
PPLSEQ > PPLPOOL (with one exception on chromosome 12
for BAP, where PPLPOOL = 0.20 and PPLSEQ = 0.17). At the
same time, the proportion of the genome showing evidence
against linkage (PPL <2%) was 74% and 79% for ASD
pooled and sequential, respectively, and 66% and 70% for
BAP pooled and sequential, respectively. Thus, for both
phenotypes, a greater proportion of the genome showed
evidence against linkage under sequential analysis, and at
these locations, the evidence against linkage tended
to be stronger. This pattern of results is consistent
with appreciable genetic heterogeneity across pedi-
grees. In what follows, we therefore rely on sequen-
tial as the primary data analytic approach to the
accumulation of evidence going forward, dropping
the ‘SEQ’ subscript.ii) ASD results (sequential)
Four loci show PPL >20% (1p36.32, PPL = 30%; 2q37.2,
PPL = 26%; 15q12, PPL = 22%; 22q13.31, PPL = 41%),
with additional loci on chromosomes 2, 8, 9, and
possibly 12 standing out above the background as well
(Figure 1a). Not surprisingly, no single pedigree gener-
ates large PPLs on its own. We note however, that on
8q12.1 a modest sequential peak appears to be driven
by a single pedigree (PPL = 19% in Ped 4); because the
sequential peak is somewhat lower than this, we can
conclude that the remaining pedigrees in aggregate
show some evidence against linkage to this locus. On
15q11.2, a single pedigree (Ped 16) shows PPL = 15%
on its own; however, the sequential peak is >15%,
suggesting that while this one pedigree accounts for
the preponderance of the evidence, one or more
additional pedigrees must also be supporting linkage
at this locus. By contrast, PPLs of comparable size
on 16q23.1-q23.2 (PPL = 19% in Ped 16) and Xp22.11-
p21.3 (PPL = 18% in Ped 5) are almost completely
erased in the sequential results. This is consis-
tent with the possibility of major loci within each
individual pedigree not found in any of the remaining
pedigrees.
Figure 1 Genome scans for (a) ASD and (b) BAP comparing ‘pooled’ with ‘sequentially updated’ results. Note that for visual clarity, the
y-axis goes from 0.0–0.5, rather than 0.0–1.0.
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Five additional loci, not seen in the ASD analyses,
show BAP PPL >20% (Figure 1b): 2q37.3 (PPL = 47%),
11q23.3 (PPL = 20%), 14q11.2 (PPL = 29%), 14q31.3
(PPL = 32%) and 15q13.3 (PPL = 20%). Considering
individual pedigrees (Figure 2b), just one salient peak
emerges, and this is on 22q13.32 (PPL = 21% in Ped 4).
Interestingly, while that locus was salient in the
omnibus (all pedigrees) ASD scan, under ASD thisparticular pedigree gives evidence against linkage
(PPL <2%) at this locus.
Table 2 shows salient results for both ASD and BAP;
Figure 3 shows ASD and BAP plots for selected chromo-
somes. Not surprisingly, at most loci, results are corre-
lated; at only 2 loci (11q23.2, 22q13.31) does one
phenotype show evidence for and the other against link-
age. Notably, of the remaining 5 loci, in only one case
(1p36.32) is the ASD score substantially higher than the
Figure 2 Genome scans for (a) ASD and (b) BAP, by individual pedigree. Note that the y-axis goes from 0.0–0.25.
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tially higher than the ASD score.
iv) Results for additional phenotypes
Figure 4 shows genome-wide results for each of the
seven secondary phenotypes (US pedigrees only). There
are multiple loci with signals greater than any seen in
the BAP analyses (with the exception of 2q37.2-q37.3,
which is higher for BAP than any of the sub-phenotypes).
None of the exploratory phenotypes NWR, RAP, or CLF
shows any signals >15% genome-wide; these phenotypesare not further considered here. It is important to keep in
mind that due to the limited size of the pedigrees, results
across phenotypes are expected to show some degree of
correlation, whether the phenotypes are measuring the
same underlying traits or not. Another way to express this
is to note that considering multiple phenotypes in a single
set of pedigrees is a form of permuting the phenotypes;
combined with selection of loci based on maximum
scores, this will tend to lead to ‘inflation’ of linkage results
[65]. Nevertheless, bearing this caveat in mind, some in-
teresting patterns emerge.
Figure 3 ASD and BAP results for selected chromosomes. Note that th
Table 2 Primary ASD and BAP findings
Locus cMa Phenotype Individual pedigrees
driving signals
ASD BAP
1p36.32 12 0.30 0.02 ASD PPL = 0.09, Ped 16
2q37.3 254 0.26b 0.47
11q23.3 126 0.00 0.20
14q11.2 0 0.04 0.29
14q31.3 84 0.02 0.32 BAP PPL = 0.08, Ped 4
15q12 12 0.22 0.199c ASD PPL = 0.15, Ped 16;
BAP PPL = 0.10, Ped 11
22q13.31 58 0.41 0.01 ASD PPL = 0.09, Ped 10
aThe cM position and locus correspond to the maximum PPL value in any
peak >20%. Additional detail can be seen in Figure 3. bThe ASD peak is at 250
cM in 2q37.2. cThe BAP peak is at 22 cM in 15q13.3.
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(Table 3). Of these, perhaps surprisingly, 3 loci are either
not supported or only marginally supported by any of the
other phenotypes. Only 1 BAP peak (2q37.2-q37.3) is well
supported by multiple subphenotypes, with only RRB giving
evidence against linkage across this locus.
Second, ANX, PRS, and SOC show multiple peaks (4
PPLs >20% for ANX, 3 for PRS, 5 for SOC, at a total of
9 loci overall). Apart from 2q37.2-q37.3 (which is best
supported by BAP), only 2 loci are strongly supported by
2 or more of these phenotypes (on 9q21.31-22.31, PRS
and SOC with slight supporting evidence from ANX; on
13q11-q12.3 ANX and PRS with evidence against link-
age for SOC). At the remaining loci, only one phenotype
clearly supports linkage; particularly notable in this re-
gard are 9p21.3 and 15q26.3, which are supported by
ANX with both PRS and SOC giving evidence against
linkage. Thus, in general, there does not seem to be a
clear pattern of correlation across these phenotypes. One y-axis goes from 0.0–0.5.
Figure 4 Genome scan for seven additional phenotypes, US pedigrees only.
Table 3 Results for BAP and secondary phenotypes for
any locus with PPL >20% for at least one phenotype (US
pedigrees only)
Locus cMa Phenotype
BAPb ANX PRS RRB SOC
2q37.2-q37.3 248–264 0.59 0.37 0.08 0.00 0.14
6p25.3-p25.2 0–8 0.04 0.00 0.26 0.03 0.04
6p25.2-24.3 12–20 0.05 0.00 0.03 0.62 0.07
8q24.13 126–134 0.04 0.03 0.03 0.00 0.37
9p21.3 44–48 0.13 0.23 0.01 0.00 0.00
9q21.31-q22.31 80–98 0.11 0.06 0.41 0.00 0.54
11q23.2-q23.3 120–126 0.26 0.00 0.01 0.00 0.00
12q21.1-q21.33 90–102 0.24 0.03 0.10 0.05 0.27
13q11-q12.3 0–26 0.14 0.51 0.32 0.00 0.01
14q31.1-q32.13 78–96 0.27 0.00 0.10 0.00 0.00
15q13.2-q13.3 20–22 0.22 0.00 0.02 0.00 0.00
15q26.3 122–128 0.01 0.33 0.01 0.00 0.00
19p13.3 10–18 0.02 0.00 0.07 0.69 0.01
19p12-q12 48–54 0.02 0.00 0.03 0.00 0.32
22q13.31 58–60 0.00 0.00 0.03 0.00 0.21
aThe cM region corresponds to the phenotype with the highest PPL,
extending out to cover PPL >10% around that peak for any phenotype. PPLs
for additional phenotypes represent the maximum within this region for the
given phenotype. bNote that these represent PPLs based on the University of
North Carolina (UNC) pedigrees only, and they are therefore not identical to
results shown in Figure 2.
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sions based on these pedigrees alone, there is some sug-
gestion that the three phenotypes might be picking up
different underlying genetic loci. Focusing on the 5 loci
with PPL >30% for either ANX, PRS, or SOC (in order to
minimize noise due to permutation over the phenotypes):
8q24.13 is supported by SOC with ANX and PRS neutral;
9q21.31-q22.31 is supported by SOC as well as PRS and
probably ANX; 13q11-q12.3 is supported by ANX as well
as PRS but not SOC; 15q26.3 is supported by ANX but
neither PRS or SOC; and 19p12-q12 is supported by SOC
but not by ANX, with PRS neutral.
Finally, a striking conclusion emerges regarding RRB.
RRB itself gives the two highest PPLs seen for any phe-
notypes (including in the primary analyses based on all
of the pedigrees): PPL = 62% at 6p25.2-24.3, and PPL =
69% at 19p13.3. Each of these loci is at best very
slightly supported by one additional phenotype, with the
remaining phenotypes either neutral or giving evidence
against linkage. Particularly notable is that even ASD
and BAP do not support these loci (Figure 5). Further-
more, RRB itself gives evidence against linkage at virtu-
ally all of the other loci in Table 3 (with the exceptions
of 6p25.3-p25.2 and 12q21.1-q21.33 where it is neutral
(note that the maximum PPLs at these 2 loci are <30%),
and this includes loci supported by BAP. Thus, clear evi-
dence emerges that RRB, while highly informative for
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the presence of multiple cases of ASD, is in fact segre-
gating independently of both BAP and the remaining
subphenotypes, and even ASD itself.
Discussion
By utilizing a set of extended pedigrees and clinical as-
sessments of a number of phenotypes in both ASD and
non-ASD relatives, we have taken an approach that dif-
fers from traditional methods used to study the genetics
of ASD. This approach has yielded several interesting
findings. First, the primary ASD results confirm roles for
known ASD loci in extended pedigrees. The four salient
loci include the Prader-Willi Angelman region on 15q
and the 22q13 deletion syndrome region, both well-
established syndromes associated with autistic features
in subsets of cases; in addition, 2q37 contains CENTG2,
which has obtained modest support as an ASD gene in
independent studies [66], and 1p36 is associated with
1p36 deletion syndrome. While considering additional
loci highlighted in the analysis of individual pedigrees
risks the appearance of ‘cherry picking’, here too the
findings highlight overlap with previously identified loci,
particularly at 8q12.1, which is the ICHD7/CHARGE
syndrome region, and Xp22, which covers PTCHD1Figure 5 RRB shows two large signals which appear to be independe
pedigrees only); (b) Chromosome 6; (c) Chromosome 19.[24,67]. While these loci have been highlighted before,
they have been discovered primarily through individual
case studies or de novo CNVs. Our results support the
importance of these loci in inherited, highly familial,
forms of ASD as well.
Secondly, in aggregate, our results strongly support
the presence of substantial between-pedigree locus het-
erogeneity for both ASD and BAP analyses. Assuming
common loci across pedigrees (PPLPOOL) produced
lower PPLs at all loci with PPL >20% compared to
allowing for different genetic loci and models across
pedigrees (PPLSEQ) (PPLSEQ also returned evidence
against linkage across a larger proportion of the gen-
ome). Moreover, as previously mentioned, support was
found for some previously implicated ASD loci in one
individual pedigree but not others. This pattern is con-
sistent with results from the CNV analyses published
over the last decade that have shown very little sharing
of loci across different families. This highlights the need
for locus- and gene-discovery methods that are robust to
locus heterogeneity, and should inform our interpret-
ation of negative as well as positive findings going
forward.
A third notable finding is that, while some peaks are
better supported by ASD and others by BAP, in only twont of ASD or BAP: (a) Genome scan for ASD, BAP and RRB (US
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dence against linkage under the other. In general, adding
the BAP to the analysis does appear to confirm the hy-
pothesis that the BAP is of relevance to ASD genetics.
Of particular interest, perhaps, are the BAP findings at
2q37.3 and 11q23.2, the first of which contains UBE2F
and the second UBE4A. Note that 11q was also reported
by Liu et al. [68] in an independent data set.
The fourth interesting finding involves the phenotypes
ANX, PRS, and/or SOC, which provided multiple loci of
interest. Given correlations across phenotypes within
pedigrees, we are sensitive to the speculative nature of
any conclusions regarding genetic relationships between
phenotypes. However, the patterns of results are consist-
ent with a model in which these sub-phenotypes are seg-
regating independently of one another at some loci, and
perhaps independently of BAP in some ‘carrier’ relatives,
but still be involved in the etiology of ASD if other
events or ‘hits’ at other loci added to the genetic liability
for ASD itself. Such interaction might be specific to par-
ticular pedigrees, to particular loci, or may generalize
across pedigrees. This seems like a fruitful area of inves-
tigation for future family-based genetic studies. The fact
that the exploratory phenotypes NWR, RAP, and CLF
showed no notable evidence for linkage across the gen-
ome also serves as a kind of negative control, suggesting
that not all phenotypes conceptually related to the defin-
ing features of autism are genetically relevant in these
pedigrees. On the other hand, these traits may simply
have been less informative in this particular data set;
only 2, 5, and 7 families are multiplex for CLF, RAP and
NWR, respectively. Additional data collection would be
needed to resolve this.
The fifth finding of this study is that RRB appears to
be entirely genetically independent of BAP and the
remaining secondary phenotypes, yet highly informative
in these families, yielding the two largest PPLs seen
across all analyses. This is consistent with recent empir-
ical measurement models that suggest that ASD is com-
posed of two key phenotypes that co-occur [69]. Under
this model, it remains to be explained why ASD itself
does not support linkage to the RRB loci. It is certainly
possible that the ASD phenotype alone is simply not
informative enough at those loci; for instance, under a
two-locus epistasis model, the meiotic information re-
garding RRB transmission might come primarily from
non-ASD individuals, with parents of those who develop
ASD tending to be homozygous for RRB genotypes and
therefore uninformative. However, this model will re-
main entirely speculative until it is possible to identify
the responsible genomic variants under the peaks.
The strengths of this study include the large number
of extended pedigrees with high quality, highly inform-
ative marker data, careful attention to measuringmultiple phenotypes for both ASD and non-ASD indi-
viduals within those pedigrees, and statistical methods,
which allowed us to take full advantage of all features
of the data. The salient limitation of the study is never-
theless sample size; despite the size of the data set,
some phenotypes remained insufficiently informative,
and particular relationships among phenotypes remain
to be confirmed and further defined. Furthermore, the
results themselves suggest considerable heterogeneity
between pedigrees, yet each pedigree on its own is not
sufficiently large to yield definitive linkage results.
Hence, most of the signals reported here remain mod-
est in size and undoubtedly not all of them represent
true linkages (although the overlap with known ASD
loci supports the efficacy of picking up true ASD genes
at several of these moderately supported loci).
Finally, the phenotypes considered here are almost
certainly still just proxies for more biologically defined
underlying features. This complicates interpretation of
results across phenotypes. For example, perhaps the
most tantalizing result is the apparent independent
segregation of RRB even from ASD within these ASD-
multiplex families. This seems contradictory, unless
ASD as diagnosed via the Autism Diagnostic Interview
and Autism Diagnostic Observation Schedule (ADI
and ADOS) is a measure for some aspects of autism
but not all. It is worth noting here that the measure-
ment of repetitive behaviors in the RBS-R is not
equivalent to what is used for the ASD diagnosis itself;
‘repetitive behaviors’ do not constitute a unitary con-
struct, and more finely grained or biologically direct
phenotypes that are likely to bring us closer to the
complex mechanisms occurring in ASD, would help
clarify the ASD-RRB relationship from a genetic point
of view [70].
Conclusions
Overall, our primary conclusions speak to key features
of the complexity of the genetic architecture of ASD: i)
there appears to be substantial between-family locus het-
erogeneity; ii) in keeping with previous epidemiologic
findings, the BAP does appear to correspond at least
roughly to sets of subclinical features segregating with
ASD within pedigrees, so that equating non-ASD rela-
tives with non-carriers of ASD genes is not correct in
general; and iii) different features of the ASD phenotype
appear to segregate independently of one another within
these pedigrees, in support of the multiple hit model ar-
ticulated by Eichler and others [71-73]. If these findings
prove correct, they pose a set of challenges to future
studies. We believe that these challenges will be met, at
least in part, by the study of additional and larger, even
more individually informative pedigrees, together with
measurement of multiple, and perhaps more biologically
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dividuals. Pedigrees of the type needed for these studies
are uncommon, but they do exist. Exploiting the many
opportunities they provide to further our understanding
of the complex genetics of ASD seems both possible and
extremely promising.Abbreviations
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